 Mind Medicine MNMD a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, has announced first patient dosing in its Phase 2b dose-optimization trial of MM-120, a pharmaceutically optimized form of lysergic acid diethylamide for the treatment of Generalized Anxiety Disorder. The Phase 2b trial in patients diagnosed with GAD is a multi-center, parallel, randomized, double-blind, placebo-controlled, dose-optimization study. 